Skip to main content
. 2017 Dec 21;7:17978. doi: 10.1038/s41598-017-18210-3

Figure 5.

Figure 5

Relative growth of LNCaP-AR cells treated with the AURKA-specific inhibitor, alisertib. The relative growth of (a) LNCaP-pcDNA3.1, (b) LNCaP-ARmo, and (c) LNCaP-ARhi cells. All cells were equally seeded on 12-well plates and treated with vehicle (DMSO) or with 10 and 100 nM alisertib (MLN8237) in triplicate. The area of the attached cells in each well was measured daily and divided by the mean from day 1. (d) The relative cell viability of LNCaP-pcDNA3.1, LNCaP-ARmo, and LNCaP-ARhi cells at day 4 measured by Alamar blue and normalized to day 1 of each cell line. NT = no treatment. *p < 0.05, **p < 0.01, and ***p < 0.001, unpaired t test.